Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Palisade Bio (PALI) Cash & Equivalents (2016 - 2025)

Palisade Bio (PALI) has disclosed Cash & Equivalents for 16 consecutive years, with $5.2 million as the latest value for Q3 2025.

  • On a quarterly basis, Cash & Equivalents fell 34.99% to $5.2 million in Q3 2025 year-over-year; TTM through Sep 2025 was $5.2 million, a 34.99% decrease, with the full-year FY2024 number at $9.8 million, down 21.0% from a year prior.
  • Cash & Equivalents was $5.2 million for Q3 2025 at Palisade Bio, down from $5.4 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $16.4 million in Q2 2023 to a low of $615000.0 in Q1 2021.
  • A 5-year average of $10.1 million and a median of $11.3 million in 2024 define the central range for Cash & Equivalents.
  • Biggest YoY gain for Cash & Equivalents was 1778.03% in 2021; the steepest drop was 93.87% in 2021.
  • Palisade Bio's Cash & Equivalents stood at $14.1 million in 2021, then fell by 12.2% to $12.4 million in 2022, then increased by 0.4% to $12.4 million in 2023, then fell by 21.0% to $9.8 million in 2024, then plummeted by 46.78% to $5.2 million in 2025.
  • Per Business Quant, the three most recent readings for PALI's Cash & Equivalents are $5.2 million (Q3 2025), $5.4 million (Q2 2025), and $7.2 million (Q1 2025).